Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer

Phase 3

Not yet recruiting

Conditions: Thyroid Cancer

Interventions: Radiation: Radioactive iodine (I-131)
Drug: metformin

First Posted Date: 2022-07-21

Last Posted Date: 2022-10-19

Lead Sponsor: Medical University of Bialystok

Target Recruit Count: 160

Registration Number: NCT05468554

Locations: 🇵🇱
Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of Bialystok, Bialystok, Poland

Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients

Conditions: Polycystic Ovary Syndrome
Metformin

Interventions: Drug: Metformin

First Posted Date: 2022-07-19

Last Posted Date: 2022-07-19

Lead Sponsor: RenJi Hospital

Target Recruit Count: 1440

Registration Number: NCT05463627

Locations: 🇨🇳
Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China

A Comparative Study of the Effect of Ayurvedic Drugs and Metformin in the Management of Diabetes Mellitus (Type II)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Chhinnavahni Kashaya Vati along with Agnimantha Kwatha
Drug: Metformin Hydrochloride

First Posted Date: 2022-07-11

Last Posted Date: 2022-07-11

Lead Sponsor: A & U Tibbia College Karol Bagh

Target Recruit Count: 48

Registration Number: NCT05451147

Locations: 🇮🇳
A and U Tibbia College, Delhi, India

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Other: Placebo
Drug: Metformin Hydrochloride

First Posted Date: 2022-07-06

Last Posted Date: 2023-06-27

Lead Sponsor: Instituto Nacional de Cancerologia de Mexico

Target Recruit Count: 312

Registration Number: NCT05445791

Locations: 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Mexico

Metformin as a Neuroprotective Therapy for Glaucoma - A Randomized Controlled Trial

Phase 3

Not yet recruiting

Conditions: Glaucoma

Interventions: Drug: Metformin
Device: Placebo

First Posted Date: 2022-06-21

Last Posted Date: 2022-06-21

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 240

Registration Number: NCT05426044

Efficacy of 1% Metformin Gel Mixed With PRF in Augmenting Narrow Ridge

Phase 3

Conditions: Horizontal Ridge Deficiency

Interventions: Drug: Metformin

First Posted Date: 2022-06-14

Last Posted Date: 2022-06-14

Lead Sponsor: Al-Azhar University

Target Recruit Count: 2

Registration Number: NCT05418452

Locations: 🇪🇬
AlAzhar universty, Cairo, Egypt

Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes

Phase 3

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: UDCA (Ursodeoxycholic acid)
Drug: Metformin

First Posted Date: 2022-06-13

Last Posted Date: 2023-05-11

Lead Sponsor: University of Banja Luka

Target Recruit Count: 60

Registration Number: NCT05416580

Locations: 🇧🇦
Public Health Institution Dom zdravlja Banja Luka, Banja Luka, Republic Of Srpska, Bosnia and Herzegovina

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine/Lixisenatide
Drug: IDegAsp
Drug: Metformin
Drug: SGLT2 inhibitor

First Posted Date: 2022-06-10

Last Posted Date: 2024-10-30

Lead Sponsor: Sanofi

Target Recruit Count: 582

Registration Number: NCT05413369

Locations: 🇨🇳
Investigational Site Number : 1560025, Harbin, China
🇨🇳
Investigational Site Number : 1560008, Baotou, China
🇨🇳
Investigational Site Number : 1560001, Beijing, China

and more 57 locations